Soligenix (NASDAQ: SNGX) and Ohr Pharmaceuticals (NASDAQ:OHRP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Soligenix and Ohr Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soligenix 0 0 2 0 3.00
Ohr Pharmaceuticals 0 0 1 0 3.00

Soligenix presently has a consensus target price of $8.00, suggesting a potential upside of 288.35%. Ohr Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 1,539.34%. Given Ohr Pharmaceuticals’ higher probable upside, analysts clearly believe Ohr Pharmaceuticals is more favorable than Soligenix.

Volatility and Risk

Soligenix has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500. Comparatively, Ohr Pharmaceuticals has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.

Valuation & Earnings

This table compares Soligenix and Ohr Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Soligenix $6.98 million 1.69 -$6.76 million ($1.36) -1.51
Ohr Pharmaceuticals N/A N/A -$24.22 million ($0.70) -0.87

Soligenix has higher revenue and earnings than Ohr Pharmaceuticals. Soligenix is trading at a lower price-to-earnings ratio than Ohr Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

2.0% of Soligenix shares are held by institutional investors. Comparatively, 7.0% of Ohr Pharmaceuticals shares are held by institutional investors. 5.0% of Soligenix shares are held by insiders. Comparatively, 17.4% of Ohr Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Soligenix and Ohr Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Soligenix -86.15% -129.88% -74.33%
Ohr Pharmaceuticals N/A -103.56% -85.09%

Summary

Ohr Pharmaceuticals beats Soligenix on 6 of the 11 factors compared between the two stocks.

Soligenix Company Profile

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Ohr Pharmaceuticals Company Profile

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.